| Name | Title | Contact Details |
|---|---|---|
Mark Finkle |
VP of Engineering (Productivity & Developer Program) | Profile |
Pinetree is a diversified investment, financial advisory and venture capital firm focused on investing in early stage micro and small cap resource companies. Pinetree`s investments are primarily in the following resource sectors: Precious Metals, Base Metals Oil and Gas, Potash, Lithium and Rare Earths, Uranium and Coal. Pinetree`s investment approach is to develop a macro view of a sector, build a position consistent with the view by identifying micro-cap opportunities within that sector and devise an exit strategy designed to maximize our relative return in light of changing fundamentals and opportunities. Pinetree is recognized as a value added partner in the resource industry.
Black and Black Surgical is a Tucker, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProHEALTH is a dynamic and growing healthcare organization, offering a wide range of employment opportunities. As we continue to grow we continually seek qualified, professional, dedicated individuals to join our team. As the largest private
Since 1972, GMCF has been providing medical peer review and consultative services, utilization and quality management review services for Medicaid Programs.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic